Podcasts

Dr Cassie Klein presents a three-year update from the phase 2 FIREFLY-1 trial evaluating tovorafenib, a weekly oral type II RAF inhibitor, in recurrent or refractory pediatric low-grade glioma. She emphasizes the importance of incorporating...

A case-based discussion on using axatilimab, including toxicity experience. 

This podcast highlights results from a recent trial on the long-term effects of ruxolitinib in transplant patients with graft-versus-host disease. 

An engaging discussion on what drives the move from steroids to a second-line or subsequent third-line therapy for chronic graft-versus-host disease? Are they really the definitions we see in trials, or are they different?

"Beyond Symptoms: Navigating Chronic Graft-Versus-Host Disease Assessment," which covers the symptomatic nature of cGVHD and provides quick tips for adequately assessing chronic graft-versus-host disease symptoms. 

Dr Eugene Hwang explores the evolving role of targeted therapies in recurrent pediatric low-grade glioma (pLGG)—balancing molecular precision, quality of life, and real-world treatment logistics in the quest for optimal care.

Dr Eugene Hwang delves into the evolving landscape of MEK and BRAF inhibitors for pediatric low-grade glioma (pLGG), comparing efficacy, side effects, and next-gen strategies shaping frontline and salvage care.